| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| ln Vivo |
Treatment with methyl 3-O-methylgallate (M3OMG; 10 and 20 mg/kg, i.p.) reduced the amount of oxidative stress brought on by NaF. 1].
1. Neuroprotective Effect against Sodium Fluoride (NaF)-Induced Oxidative Stress: Male Wistar rats were randomly divided into 4 groups (n=6/group): Control (distilled water), NaF (100 mg/kg/day via oral gavage), Methyl 3-O-methylgallate (10 mg/kg/day via intraperitoneal injection) + NaF, and Methyl 3-O-methylgallate (20 mg/kg/day via intraperitoneal injection) + NaF. Treatment lasted for 30 days. NaF administration significantly increased brain malondialdehyde (MDA) levels (lipid peroxidation marker) and decreased superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) activities (antioxidant enzymes), while reducing glutathione (GSH) content. Methyl 3-O-methylgallate treatment dose-dependently reversed these effects, restoring antioxidant enzyme activities and GSH levels while reducing MDA accumulation. Histopathological analysis revealed that Methyl 3-O-methylgallate alleviated NaF-induced neuronal degeneration, cytoplasmic vacuolation, and inflammatory cell infiltration in the brain [1] 2. Mechanism of Action: The neuroprotective effects of Methyl 3-O-methylgallate were attributed to its ability to scavenge reactive oxygen species (ROS), enhance antioxidant defense systems, and reduce lipid peroxidation in the brain tissue of NaF-exposed rats [1] |
|---|---|
| Animal Protocol |
Animal/Disease Models: 50 male Wistar rats (8-12, 7 days old, 200-250g) [1].
Doses: 10 and 20 mg/kg. Route of Administration: IP 1 week. Experimental Results: Mitigated NaF-induced oxidative stress by normalizing TBARS levels, reducing glutathione levels, and restoring weakened antioxidant enzyme activities. 1. Experimental Design: Male Wistar rats (200-250 g) were housed under controlled conditions (12-hour light/dark cycle, 22±2°C, 50-60% humidity) with free access to food and water. After a 7-day acclimation period, rats were divided into 4 groups: Control (distilled water), NaF (100 mg/kg/day via oral gavage), Methyl 3-O-methylgallate (10 mg/kg/day via intraperitoneal injection) + NaF, and Methyl 3-O-methylgallate (20 mg/kg/day via intraperitoneal injection) + NaF. Methyl 3-O-methylgallate was dissolved in dimethyl sulfoxide (DMSO) and diluted with saline to the desired concentration. Treatments were administered daily for 30 days. On day 31, rats were sacrificed under anesthesia, and brain tissues were collected for biochemical and histological analyses [1] |
| Toxicity/Toxicokinetics |
1. Safety evaluation: Compared with the control group, no significant changes were observed in body weight, food/water intake or organ weight (liver, kidney, spleen) in the methyl 3-O-methylgallate treatment group. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN) and creatinine (Cr) levels remained within the normal range, indicating that no hepatotoxicity or nephrotoxicity was observed at the test dose (10-20 mg/kg/day for 30 days) [1].
|
| References | |
| Additional Infomation |
It has been reported that methyl 3,4-dihydroxy-5-methoxybenzoate is found in red maple (Acer rubrum) and hooked comb (Crinodendron hookerianum), and there are related data reports.
1. Background: methyl 3-O-methylgallate is a natural phenolic compound isolated from the seeds of kola nut (Garcinia kola), known for its antioxidant and anti-inflammatory properties. This study investigated its protective effect against sodium fluoride (NaF)-induced neurotoxicity, a common environmental pollutant associated with cognitive impairment and neurodegenerative diseases [1]. 2. Significance: The results suggest that methyl 3-O-methylgallate may have therapeutic potential for the prevention or treatment of oxidative stress-related neurological diseases, but further research is needed to verify its efficacy and explore its potential molecular mechanisms [1]. |
| Molecular Formula |
C9H10O5
|
|---|---|
| Molecular Weight |
198.1727
|
| Exact Mass |
198.052
|
| CAS # |
3934-86-9
|
| PubChem CID |
99622
|
| Appearance |
Off-white to yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
391.7±37.0 °C at 760 mmHg
|
| Flash Point |
160.5±20.0 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.568
|
| LogP |
1.49
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
14
|
| Complexity |
205
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
LVVUKXKEXOTUPV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H10O5/c1-13-7-4-5(9(12)14-2)3-6(10)8(7)11/h3-4,10-11H,1-2H3
|
| Chemical Name |
methyl 3,4-dihydroxy-5-methoxybenzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~504.62 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (12.62 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (12.62 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (12.62 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.0462 mL | 25.2309 mL | 50.4617 mL | |
| 5 mM | 1.0092 mL | 5.0462 mL | 10.0923 mL | |
| 10 mM | 0.5046 mL | 2.5231 mL | 5.0462 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
